NCT06656806View on ClinicalTrials.gov

Efficacy and Safety of Inhaled NC-107 As Compared to Placebo After 4 Weeks of Treatment in Patients with Anxiety

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

May 1, 2025

Study Completion Date

May 1, 2025

Conditions
Generalized Anxiety Disorder
Interventions
DRUG

Measure concentrations of CBD in spot urine collections from subjects treated with inhaled CBD

Measure concentrations of CBD in spot urine collections from subjects with generalized anxiety disorder treated with inhaled CBD

DRUG

Determine the presence and concentration of CBD in subject's plasma with inhaled CBD

Determine the presence and concentration of CBD in plasma of subjects with generalized anxiety disorder treated with inhaled CBD

Trial Locations (1)

75006

Punzi Medical Center, Carrollton

Sponsors

Collaborators (1)

Nutraceutical Corporation
All Listed Sponsors
collaborator

Nutraceutical Corporation

UNKNOWN

lead

Trinity Hypertension & Metabolic Research Institute

OTHER

NCT06656806 - Efficacy and Safety of Inhaled NC-107 As Compared to Placebo After 4 Weeks of Treatment in Patients with Anxiety | Biotech Hunter | Biotech Hunter